Artwork

Conteúdo fornecido por Quest Diagnostics. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Quest Diagnostics ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

Trends in drug testing resulting from the COVID-19 pandemic

38:17
 
Compartilhar
 

Manage episode 300792531 series 2925652
Conteúdo fornecido por Quest Diagnostics. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Quest Diagnostics ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

The convergence of the opioid epidemic and the coronavirus disease 2019 (COVID-19) pandemic has created new healthcare challenges. Health systems, from a system- and individual clinician-level, are more important than ever in the pursuit of addressing the epidemic within the pandemic.

In this session, Dr Gudin discusses:

  • Recently-published data by Quest that demonstrates decreased drug testing overall, with increased positivity for high-risk drugs and dangerous drug combinations
  • Tools and practices for clinicians to assess and stratify patients for potential prescription drug abuse
  • System-level strategies that employ an integrated care delivery approach, including leveraging community and diagnostics partnerships, to support impacted patient populations

Jeffrey Gudin, MD; Executive Director, Medical Affairs, Drug Monitoring & Toxicology

Dr Gudin is an active speaker and advisor whose clinical and research interests include postoperative pain management; opioid abuse, and potential solutions; and increasing clinical awareness of pain assessment and risk management. Board-certified in pain management, addiction medicine, and hospice and palliative medicine, Dr Gudin is also a medical acupuncturist. He serves as co-Editor-at-Large for Practical Pain Management.

----more----

------------------------------

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve healthcare management. Quest Diagnostics annually serves 1 in 3 adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

More information is available at www.QuestDiagnostics.com

  continue reading

18 episódios

Artwork
iconCompartilhar
 
Manage episode 300792531 series 2925652
Conteúdo fornecido por Quest Diagnostics. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Quest Diagnostics ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

The convergence of the opioid epidemic and the coronavirus disease 2019 (COVID-19) pandemic has created new healthcare challenges. Health systems, from a system- and individual clinician-level, are more important than ever in the pursuit of addressing the epidemic within the pandemic.

In this session, Dr Gudin discusses:

  • Recently-published data by Quest that demonstrates decreased drug testing overall, with increased positivity for high-risk drugs and dangerous drug combinations
  • Tools and practices for clinicians to assess and stratify patients for potential prescription drug abuse
  • System-level strategies that employ an integrated care delivery approach, including leveraging community and diagnostics partnerships, to support impacted patient populations

Jeffrey Gudin, MD; Executive Director, Medical Affairs, Drug Monitoring & Toxicology

Dr Gudin is an active speaker and advisor whose clinical and research interests include postoperative pain management; opioid abuse, and potential solutions; and increasing clinical awareness of pain assessment and risk management. Board-certified in pain management, addiction medicine, and hospice and palliative medicine, Dr Gudin is also a medical acupuncturist. He serves as co-Editor-at-Large for Practical Pain Management.

----more----

------------------------------

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve healthcare management. Quest Diagnostics annually serves 1 in 3 adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

More information is available at www.QuestDiagnostics.com

  continue reading

18 episódios

Todos os episódios

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências